(“Cyprotex” or “the Company”)
Cyprotex to expand its UK facility into BioHub at Alderley Park
1st October 2013; Cyprotex PLC (AIM:CRX), a specialist ADME-Tox Contract Research Organisation, announced today its plans for the expansion of its UK facility into BioHub, a new bioscience centre at AstraZeneca’s Alderley Park research campus near Manchester, England.
BioHub will provide Cyprotex with additional capacity for laboratories and office space. The new laboratories include fully equipped cell culture facilities and radiochemical handling capabilities enabling Cyprotex to continue its growth strategy into new areas supporting preclinical drug discovery projects.
This expansion follows highly encouraging growth figures for the business in the first six months of the year, with a revenue increase of 22.3% in H1 compared to the same period in 2012 and a record half yearly operating profit of £317,000. Performance remains strong across all of our geographical markets and our main service operations of high throughput ADME, customised ADME and toxicology.
Dr Anthony Baxter, Cyprotex’s Chief Executive Officer, comments: “As we continue to see significant growth in our business, it has been necessary to expand our facilities to meet the increased demand. We are therefore delighted to announce the signing of a lease for new cutting-edge facilities at BioHub in Alderley Park. The location of the facility is ideal for transport links, both by air and road, which is important as Cyprotex expands its international footprint.”
For further information:
Tel: +44 (0) 1625 505 100
Dr Anthony Baxter, Chief Executive Office
John Dootson, Chief Financial Officer
Mark Warburton, Chief Operating Officer and Legal Counsel
N+1 Singer (Nomad and broker to Cyprotex)
Tel: +44 (0)20 7496 3000
Notes to Editors
About Cyprotex PLC
Cyprotex is based in Macclesfield, near Manchester in the UK, and Watertown, MA in the US and is listed on the AIM market of the London Stock Exchange (CRX). The company was established in 1999 and works with more than 700 partners ranging from small biotech’s to large pharma companies. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The company’s core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr® toxicity prediction technology, and predictive modelling using PBPK and QSAR techniques, including Cloe® PK for in vivo PK prediction. For more information, see www.cyprotex.com.